RiteMED Mefenamic Acid

Mefenamic acid

Relief of mild to moderate pain eg, headache, dental pain, pain after childbirth or surgery, primary dysmenorrhea, & menorrhagia (heavy menstrual period) due to dysfunctional causes. Relief of pain associated w/ musculoskeletal & joint disorders including OA & RA.

Adult & childn >14 yr 1-2 tabs 250 mg tab or 1 tab 500 mg every 8 hr. Relief of dysmenorrhea & premenstrual syndrome 1-2 tabs 250 mg tab or 1 tab 500 mg every 8 hr, should not be given for >7 days.

Should be taken with food: Take immediately after meals.

Hypersensitivity w/ mefenamic acid, aspirin or any other NSAID. Patient currently taking aspirin or other NSAIDs. Patient had or is suffering from stomach ulcers, bleeding or other stomach problems eg, inflammatory bowel disease; diarrhea w/ mefenamic acid in the past. Severe heart, liver or kidney disease, bleeding in the brain or other bleeding disorders, high K in the blood, dengue fever. Pre-op pain in the setting of CABG surgery. Pregnancy (3rd trimester). Lactation. Childn & adolescent <14 yr. 250 mg: Bronchospasm, angioedema, nasal polyps or allergic-type reactions after taking aspirin or other NSAIDs. 500 mg: Asthma, urticaria.

May increase risk of serious CV thrombotic events, MI, & stroke; patients w/ CV disease or risk factors for CV disease; ischemic heart disease (eg, MI &/or angina), cerebrovascular disease (eg, stroke, CVA, transient ischemic attacks &/or amaurosis fugax) &/or CHF. Serious GI adverse events including bleeding, ulceration, & perforation of the stomach, small or large intestines; increased stomach bleeding risk in patients w/ stomach ulcers or bleeding problems; taking blood thinning (anticoagulant) or steroid medicine; medicines containing prescription or nonprescription NSAIDs (aspirin, ibuprofen or others); takes 3 or more alcoholic drinks everyday. Prolonged use may increase risk of heart attack or stroke. Elderly patients suffering from dehydration & kidney disease. Not recommended for use w/ other NSAIDs, w/ the exception of low-dose aspirin for CV prophylaxis. Interferes w/ platelet function; used w/ caution in patients w/ intracranial hemorrhage & bleeding diathesis. Onset of new or worsening of preexisting HTN; closely monitor BP during initiation & throughout the course of therapy. Caution in patients w/ fluid retention or heart failure. Patients on prolonged corticosteroid therapy should be tapered slowly. Administration of NSAID may cause a dose-dependent reduction in prostaglandin formation & in renal blood flow which may precipitate overt renal decompensation. Patients at greater risk of are those w/ impaired renal function, heart failure, liver dysfunction, taking diuretics & ACE inhibitors. Administer w/ caution to patients w/ preexisting asthma. Discontinue use at the 1st appearance of skin rash, mucosal lesions, or any sign of hypersensitivity. Check for Hb or hematocrit in patients w/ long-term treatment w/ NSAIDs. Patients w/ symptoms &/or signs suggesting liver dysfunction, or in whom an abnormal liver test occurs should be evaluated. Discontinue if clinical signs & symptoms consistent w/ liver disease develop or if systemic manifestations occur (eg, eosinophilia, rash). Prolonged use of any types of analgesic may worsen headache. Increased risk of aseptic meningitis. Caution should be exercised in patients suffering from epilepsy. Liver dysfunction, rash, blood dyscrasias or development of diarrhea should be monitored in patients on prolonged therapy. May affect the ability to drive & use machine. Not recommended in patients w/ advanced renal disease. Elderly.

Abdominal pain, abnormal kidney function, anemia, constipation, diarrhea, dizziness, dyspepsia, edema, elevated liver enzymes (eg, ALT or AST), flatulence, GI ulcers (gastric/duodenal), gross bleeding/perforation, headache, heartburn, increased bleeding time, itching, nausea, rashes, ringing in the ears (tinnitus), & vomiting.

Increase risk of renal impairment w/ ACE inhibitors (eg, captopril, fosinopril, imidapril, enalapril) & AIIA (eg, losartan, telmisartan). May reduce excretion of aminoglycosides (eg, gentamicin) & MTX. Increased Cmax and AUC w/ antacid. Increased risk of GI ulceration or bleeding w/ anticoagulants (eg, warfarin), antiplatelet agents (eg, aspirin, clopidogrel, cilostazol), corticosteroids & SSRIs (eg, fluoxetine, citalopram, sertraline). Increased adverse effects w/ aspirin, other NSAIDs (eg, ibuprofen, ketorolac, meloxicam) including COX-2 selective inhibitors (eg, celecoxib, etoricoxib). Reduced GFR & increase plasma cardiac glycoside levels w/ cardiac glycosides (eg, digoxin). Increased risk of nephrotoxicity w/ ciclosporin & tacrolimus. Reduced the natriuretic effects w/ diuretics (eg, thiazides, furosemide). Altered safety & efficacy w/ drugs affecting hepatic microsomal enzymes. Reduce renal excretion w/ lithium. Concomitant use w/ mifepristone can reduce its effects. Increased risk of hypoglycemia. Reduced metabolism & prolonged t_½ w/ oral hypoglycemic agents (sulfonylureas eg, gliclazide, glipizide, glimepiride). Reduced metabolism & elimination w/ probenecid. Concomitant use w/ protein-bound drugs (eg, hydantoins, sulfonamides & sulfonylureas). Increased risk of convulsions w/ quinolones antibiotics. Increased risk of hematological toxicity w/ zidovudine.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.

250 mg:Non-Rx;500 mg:Rx